Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

IF 96.2 1区医学 Q1 MEDICINE, GENERAL & INTERNAL New England Journal of Medicine Pub Date : 2024-09-15 DOI:10.1056/nejmoa2401726

Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Parikh, Min Yuen Teo, Randy F. Sweis, Daniel M. Geynisman, Petros Grivas, Gurkamal Chatta, Zachery Roger Reichert, Joseph W. Kim, Mehmet Asim Bilen, Bradley McGregor, Parminder Singh, Abhishek Tripathi, Suzanne Cole, Nicholas Simon, Scot Niglio, Lisa Ley, Lisa Cordes, Sandy Srinivas, Jiaoti Huang, Meagan Odegaard, Colleen Watt, Daniel Petrylak, Jeannie Hoffman-Censits, Yujia Wen, Olwen Hahn, Cecilia Mitchell, Alan Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J. Morris, and Jonathan E. Rosenberg From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, Nati..

{"title":"Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma","authors":"Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Parikh, Min Yuen Teo, Randy F. Sweis, Daniel M. Geynisman, Petros Grivas, Gurkamal Chatta, Zachery Roger Reichert, Joseph W. Kim, Mehmet Asim Bilen, Bradley McGregor, Parminder Singh, Abhishek Tripathi, Suzanne Cole, Nicholas Simon, Scot Niglio, Lisa Ley, Lisa Cordes, Sandy Srinivas, Jiaoti Huang, Meagan Odegaard, Colleen Watt, Daniel Petrylak, Jeannie Hoffman-Censits, Yujia Wen, Olwen Hahn, Cecilia Mitchell, Alan Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J. Morris, and Jonathan E. Rosenberg From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, Nati..","doi":"10.1056/nejmoa2401726","DOIUrl":null,"url":null,"abstract":"Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive uro...","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2000,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/nejmoa2401726","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive uro...

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肌肉浸润性尿路上皮癌的 Pembrolizumab 辅助治疗与观察治疗比较

肌层浸润性尿路上皮癌是一种侵袭性疾病，复发率很高。pembrolizumab作为辅助疗法对高风险肌层浸润性尿路癌患者是否有效？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

New England Journal of Medicine 医学-医学：内科

CiteScore

145.40

自引率

0.60%

发文量

1839

审稿时长

1 months

期刊介绍： The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.

期刊最新文献

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. From Evidence to Policy - Finding Authoritative Sources of Information on Health. Long Covid Defined. Invasive Treatment Strategy for Older Patients with Myocardial Infarction.